COVID-19 相关并发症及潜在治疗靶点。
COVID-19 associated complications and potential therapeutic targets.
机构信息
University of the Sciences, 600 South 43rd Street, Philadelphia, PA, 19104, USA.
University of the Sciences, 600 South 43rd Street, Philadelphia, PA, 19104, USA.
出版信息
Eur J Pharmacol. 2020 Nov 5;886:173548. doi: 10.1016/j.ejphar.2020.173548. Epub 2020 Sep 12.
The global pandemic COVID-19, caused by novel coronavirus SARS-CoV-2, has emerged as severe public health issue crippling world health care systems. Substantial knowledge has been generated about the pathophysiology of the disease and possible treatment modalities in a relatively short span of time. As of August 19, 2020, there is no approved drug for the treatment of COVID-19. More than 600 clinical trials for potential therapeutics are underway and the results are expected soon. Based on early experience, different treatment such as anti-viral drugs (remdesivir, favipiravir, lopinavir/ritonavir), corticosteroids (methylprednisolone, dexamethasone) or convalescent plasma therapy are recommended in addition to supportive care and symptomatic therapy. There are several treatments currently being investigated to address the pathological conditions associated with COVID-19. This review provides currently available information and insight into pathophysiology of the disease, potential targets, and relevant clinical trials for COVID-19.
由新型冠状病毒 SARS-CoV-2 引起的全球大流行 COVID-19 已经成为严重的公共卫生问题，使世界卫生保健系统陷入瘫痪。在相对较短的时间内，已经产生了大量关于该疾病病理生理学和可能治疗方法的知识。截至 2020 年 8 月 19 日，尚无治疗 COVID-19 的批准药物。目前正在进行 600 多项针对潜在疗法的临床试验，预计很快将公布结果。根据早期经验，除了支持性护理和对症治疗外，还建议使用抗病毒药物（瑞德西韦、法匹拉韦、洛匹那韦/利托那韦）、皮质类固醇（甲泼尼龙、地塞米松）或恢复期血浆疗法等不同治疗方法。目前正在研究几种治疗方法，以解决与 COVID-19 相关的病理状况。本综述提供了 COVID-19 的疾病病理生理学、潜在靶点和相关临床试验的现有信息和见解。
Zotero 插件